logo

FDA Calendar

Share
Company Name Seattle Genetics Inc.
Drug Name Tucatinib (NDA)
Event Name FDA decision on Tucatinib for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer
Event Date 08/20/2020
Outcome Date
Outcome
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar

>